Mycoplasma genitalium acquisition and macrolide resistance after initiation of HIV pre-exposure prophylaxis in men who have sex with men
| Autor: | Sanne Steyaert, Stefanie De Buyser, Hilde Mahieu, Marijke Reynders, Veerle Grootaert, Patrick Descheemaeker, Stefaan J. Vandecasteele, Jens Van Praet, Barbara Van den Bergh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0303 health sciences
medicine.medical_specialty Chlamydia biology 030306 microbiology business.industry Incidence (epidemiology) Dermatology Mycoplasma medicine.disease Azithromycin biology.organism_classification medicine.disease_cause Men who have sex with men 03 medical and health sciences Pre-exposure prophylaxis 0302 clinical medicine Infectious Diseases Internal medicine medicine Syphilis 030212 general & internal medicine business Mycoplasma genitalium medicine.drug |
| Zdroj: | Sexually Transmitted Infections. 96:396-398 |
| ISSN: | 1472-3263 1368-4973 |
| DOI: | 10.1136/sextrans-2019-054335 |
| Popis: | ObjectivesRecent evidence shows that patients using HIV pre-exposure prophylaxis (PrEP) have an increased rate of bacterial STIs, including syphilis, chlamydia and gonorrhoea. Our study aimed to describe the acquisition and the susceptibility for macrolides of Mycoplasma genitalium in men who have sex with men (MSM) on PrEP.MethodsWe studied all MSM who started PrEP in the AZ Sint-Jan Hospital Bruges from 1 June 2017 to 31 March 2019 with at least one follow-up visit. Patients were screened for M. genitalium and other STIs with pooled rectal swabs, pharyngeal swabs and first-voided urine, and blood samples at baseline and quarterly intervals after initiating PrEP. TaqMan Array Card technology was used to detect M. genitalium and determine macrolide-resistance mediating mutations in region V of the 23S rRNA gene (A2058G, A2059G, A2058C and others). Patients with an STI were treated based on a national guideline.Results131 MSM (median age 40 years, range 20–79) were included in the study. The median follow-up time was 12 months (IQR 6.1–17). Baseline prevalence of M. genitalium was 6.9% and incidence rate after PrEP initiation was 28.8 per 100 person-years (95% CI 21.7 to 37.2), without significant differences in proportions between the first four quarterly intervals. All but one acquisitions were asymptomatic. Younger age and positivity for M. genitalium at baseline were significantly associated with incident M. genitalium acquisition. The observed proportion of macrolide resistance increased not significantly from 44% at baseline to 57%–86% after PrEP initiation. None of the 27 macrolide-resistant M. genitalium acquisitions could be linked to azithromycin exposure in the three preceding months.ConclusionsAfter initiation of PrEP, we found a stable incidence of almost exclusively asymptomatic M. genitalium. However, a non-significant trend of an increased percentage of macrolide-resistant strains was observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|